vs
Lantheus Holdings, Inc.（LNTH）与UiPath, Inc.（PATH）财务数据对比。点击上方公司名可切换其他公司
UiPath, Inc.的季度营收约是Lantheus Holdings, Inc.的1.0倍（$411.1M vs $406.8M），UiPath, Inc.净利率更高（48.4% vs 13.3%，领先35.1%），UiPath, Inc.同比增速更快（15.9% vs 4.0%），Lantheus Holdings, Inc.自由现金流更多（$81.4M vs $25.1M），过去两年Lantheus Holdings, Inc.的营收复合增速更高（4.9% vs 0.7%）
Lantheus Holdings是一家全球性医疗保健企业，专注于研发、生产及商业化创新诊断显像剂与相关解决方案，产品覆盖肿瘤学、心脏病学、泌尿学等核心医疗领域，主要市场遍及北美及全球其他重点地区。
UiPath是一家全球化软件企业，专注于开发人工智能、智能自动化及流程编排类软件，其产品支持用户搭建与调度AI代理，实现复杂业务流程、工作流的自动化运行，助力各行业客户提升运营效率、降低人力成本。
LNTH vs PATH — 直观对比
营收规模更大
PATH
是对方的1.0倍
$406.8M
营收增速更快
PATH
高出11.9%
4.0%
净利率更高
PATH
高出35.1%
13.3%
自由现金流更多
LNTH
多$56.3M
$25.1M
两年增速更快
LNTH
近两年复合增速
0.7%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $406.8M | $411.1M |
| 净利润 | $54.1M | $198.8M |
| 毛利率 | 59.2% | 83.3% |
| 营业利润率 | 19.0% | 3.2% |
| 净利率 | 13.3% | 48.4% |
| 营收同比 | 4.0% | 15.9% |
| 净利润同比 | 558.8% | 1966.2% |
| 每股收益（稀释后） | $0.86 | $0.37 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LNTHPATH
| Q4 25 | $406.8M | $411.1M | ||
| Q3 25 | $384.0M | $361.7M | ||
| Q2 25 | $378.0M | $356.6M | ||
| Q1 25 | $372.8M | $423.6M | ||
| Q4 24 | $391.1M | $354.7M | ||
| Q3 24 | $378.7M | $316.3M | ||
| Q2 24 | $394.1M | $335.1M | ||
| Q1 24 | $370.0M | $405.3M |
净利润LNTHPATH
| Q4 25 | $54.1M | $198.8M | ||
| Q3 25 | $27.8M | $1.6M | ||
| Q2 25 | $78.8M | $-22.6M | ||
| Q1 25 | $72.9M | $51.8M | ||
| Q4 24 | $-11.8M | $-10.7M | ||
| Q3 24 | $131.1M | $-86.1M | ||
| Q2 24 | $62.1M | $-28.7M | ||
| Q1 24 | $131.1M | $33.9M |
毛利率LNTHPATH
| Q4 25 | 59.2% | 83.3% | ||
| Q3 25 | 57.9% | 82.2% | ||
| Q2 25 | 63.8% | 82.1% | ||
| Q1 25 | 63.8% | 84.8% | ||
| Q4 24 | 63.5% | 82.0% | ||
| Q3 24 | 63.9% | 80.0% | ||
| Q2 24 | 64.9% | 83.5% | ||
| Q1 24 | 65.4% | 86.8% |
营业利润率LNTHPATH
| Q4 25 | 19.0% | 3.2% | ||
| Q3 25 | 11.4% | -5.6% | ||
| Q2 25 | 23.3% | -4.6% | ||
| Q1 25 | 27.4% | 7.9% | ||
| Q4 24 | 29.1% | -12.2% | ||
| Q3 24 | 35.3% | -32.7% | ||
| Q2 24 | 26.1% | -14.8% | ||
| Q1 24 | 28.8% | 3.7% |
净利率LNTHPATH
| Q4 25 | 13.3% | 48.4% | ||
| Q3 25 | 7.2% | 0.4% | ||
| Q2 25 | 20.8% | -6.3% | ||
| Q1 25 | 19.6% | 12.2% | ||
| Q4 24 | -3.0% | -3.0% | ||
| Q3 24 | 34.6% | -27.2% | ||
| Q2 24 | 15.8% | -8.6% | ||
| Q1 24 | 35.4% | 8.4% |
每股收益（稀释后）LNTHPATH
| Q4 25 | $0.86 | $0.37 | ||
| Q3 25 | $0.41 | $0.00 | ||
| Q2 25 | $1.12 | $-0.04 | ||
| Q1 25 | $1.02 | $0.09 | ||
| Q4 24 | $-0.18 | $-0.02 | ||
| Q3 24 | $1.79 | $-0.15 | ||
| Q2 24 | $0.88 | $-0.05 | ||
| Q1 24 | $1.87 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $359.1M | $1.4B |
| 总债务越低越好 | $568.7M | — |
| 股东权益账面价值 | $1.1B | $1.9B |
| 总资产 | $2.2B | $2.9B |
| 负债/权益比越低杠杆越低 | 0.52× | — |
8季度趋势，按日历期对齐
现金及短期投资LNTHPATH
| Q4 25 | $359.1M | $1.4B | ||
| Q3 25 | $382.0M | $1.4B | ||
| Q2 25 | $695.6M | $1.6B | ||
| Q1 25 | $938.5M | $1.6B | ||
| Q4 24 | $912.8M | $1.6B | ||
| Q3 24 | $866.4M | $1.7B | ||
| Q2 24 | $757.0M | $1.9B | ||
| Q1 24 | $718.3M | $1.9B |
总债务LNTHPATH
| Q4 25 | $568.7M | — | ||
| Q3 25 | $567.9M | — | ||
| Q2 25 | $566.8M | — | ||
| Q1 25 | $566.1M | — | ||
| Q4 24 | $565.3M | — | ||
| Q3 24 | $613.0K | — | ||
| Q2 24 | $563.2M | — | ||
| Q1 24 | $562.5M | — |
股东权益LNTHPATH
| Q4 25 | $1.1B | $1.9B | ||
| Q3 25 | $1.1B | $1.7B | ||
| Q2 25 | $1.2B | $1.7B | ||
| Q1 25 | $1.2B | $1.8B | ||
| Q4 24 | $1.1B | $1.7B | ||
| Q3 24 | $1.2B | $1.8B | ||
| Q2 24 | $1.0B | $2.0B | ||
| Q1 24 | $945.5M | $2.0B |
总资产LNTHPATH
| Q4 25 | $2.2B | $2.9B | ||
| Q3 25 | $2.3B | $2.6B | ||
| Q2 25 | $2.1B | $2.6B | ||
| Q1 25 | $2.1B | $2.9B | ||
| Q4 24 | $2.0B | $2.7B | ||
| Q3 24 | $2.0B | $2.7B | ||
| Q2 24 | $1.9B | $2.8B | ||
| Q1 24 | $1.8B | $3.0B |
负债/权益比LNTHPATH
| Q4 25 | 0.52× | — | ||
| Q3 25 | 0.51× | — | ||
| Q2 25 | 0.49× | — | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 0.52× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.55× | — | ||
| Q1 24 | 0.59× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $90.2M | $28.3M |
| 自由现金流经营现金流 - 资本支出 | $81.4M | $25.1M |
| 自由现金流率自由现金流/营收 | 20.0% | 6.1% |
| 资本支出强度资本支出/营收 | 2.2% | 0.8% |
| 现金转化率经营现金流/净利润 | 1.67× | 0.14× |
| 过去12个月自由现金流最近4个季度 | $354.1M | — |
8季度趋势，按日历期对齐
经营现金流LNTHPATH
| Q4 25 | $90.2M | $28.3M | ||
| Q3 25 | $105.3M | $41.6M | ||
| Q2 25 | $87.1M | $119.0M | ||
| Q1 25 | $107.6M | $146.1M | ||
| Q4 24 | $157.7M | $28.1M | ||
| Q3 24 | $175.1M | $46.4M | ||
| Q2 24 | $84.7M | $100.0M | ||
| Q1 24 | $127.2M | $145.6M |
自由现金流LNTHPATH
| Q4 25 | $81.4M | $25.1M | ||
| Q3 25 | $94.7M | — | ||
| Q2 25 | $79.1M | $106.2M | ||
| Q1 25 | $98.8M | $138.7M | ||
| Q4 24 | $141.4M | $23.2M | ||
| Q3 24 | $159.3M | $45.0M | ||
| Q2 24 | $73.5M | $98.8M | ||
| Q1 24 | $119.0M | $141.8M |
自由现金流率LNTHPATH
| Q4 25 | 20.0% | 6.1% | ||
| Q3 25 | 24.7% | — | ||
| Q2 25 | 20.9% | 29.8% | ||
| Q1 25 | 26.5% | 32.7% | ||
| Q4 24 | 36.1% | 6.5% | ||
| Q3 24 | 42.0% | 14.2% | ||
| Q2 24 | 18.7% | 29.5% | ||
| Q1 24 | 32.2% | 35.0% |
资本支出强度LNTHPATH
| Q4 25 | 2.2% | 0.8% | ||
| Q3 25 | 2.8% | 0.0% | ||
| Q2 25 | 2.1% | 3.6% | ||
| Q1 25 | 2.3% | 1.7% | ||
| Q4 24 | 4.2% | 1.4% | ||
| Q3 24 | 4.2% | 0.4% | ||
| Q2 24 | 2.8% | 0.4% | ||
| Q1 24 | 2.2% | 0.9% |
现金转化率LNTHPATH
| Q4 25 | 1.67× | 0.14× | ||
| Q3 25 | 3.79× | 26.25× | ||
| Q2 25 | 1.11× | — | ||
| Q1 25 | 1.47× | 2.82× | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.34× | — | ||
| Q2 24 | 1.36× | — | ||
| Q1 24 | 0.97× | 4.29× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LNTH
| Radiopharmaceutical Oncology | $240.2M | 59% |
| Definity | $85.3M | 21% |
| Strategic Partnerships And Other | $23.3M | 6% |
| Techne Lite | $21.0M | 5% |
| Licenseand Royalty Revenues | $17.4M | 4% |
| Other | $13.6M | 3% |
| Other Precision Diagnostics | $5.9M | 1% |
PATH
| Subscription Services | $247.6M | 60% |
| License | $150.0M | 36% |
| Professional Services And Other | $13.5M | 3% |
